Clinical Trials
10 trialsNCT06670911 2025-02-24
ACCESS-I
Instituto Nacional de Cancer, Brazil
Phase 2 Recruiting
NCT05648019 2023-03-09
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital
Phase 2 Recruiting
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT03601624 2018-11-14
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Phase 2 Unknown
NCT03666221 2018-09-11
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT01380275 2014-09-25
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
National Cancer Center, Korea
Phase 2 Unknown
NCT00412919 2013-12-16
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
Bayside Health
Phase 2 Terminated
NCT01086488 2011-07-08
FOSCAN
Ministry of Health, Malaysia
Phase 2 Unknown
NCT01300156 2011-02-21
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
National Cancer Center, Korea
Phase 2 Unknown